'Pegifn rbv' presentation slideshows

Executive Director, Hepatitis C Support Project hcvadvocate hbvadvocate

507 views • 41 slides

Resistance to Direct Acting Antiviral Therapy

Resistance to Direct Acting Antiviral Therapy. Resistance to HCV DAAs: What is the threat level?. HCV Biology is the basis for resistance. HCV biology is the basis for cure. Frequency of Protease Resistance Mutations Prior to Therapy.

618 views • 39 slides

How Will New HCV Therapies Overcome the Challenges of Current Regimens?

How Will New HCV Therapies Overcome the Challenges of Current Regimens?. Jordan J. Feld, MD, MPH Assistant Professor of Medicine University of Toronto Hepatologist Toronto Western Hospital Liver Centre McLaughlin-Rotman Centre for Global Health Toronto, Ontario, Canada.

488 views • 38 slides

How Will New HCV Therapies Overcome the Challenges of Current Regimens?

How Will New HCV Therapies Overcome the Challenges of Current Regimens?. Jordan J. Feld, MD, MPH Assistant Professor of Medicine University of Toronto Hepatologist Toronto Western Hospital Liver Centre McLaughlin-Rotman Centre for Global Health Toronto, Ontario, Canada.

492 views • 38 slides

HIV / Hepatitis C Coinfection : From guesswork to Guidelines

Chris Fraser, MD Medical Director, Cool Aid Community Health Centre Clinical Faculty, UBC Faculty of Medicine. HIV / Hepatitis C Coinfection : From guesswork to Guidelines. HIV / Hepatitis C CoInfection. HIV infection as a roadmap for HCV and Coinfection HIV/ Hep C Coinfection overview

470 views • 37 slides

HIV / Hepatitis C Coinfection : From guesswork to Guidelines

Chris Fraser, MD Medical Director, Cool Aid Community Health Centre Clinical Faculty, UBC Faculty of Medicine. HIV / Hepatitis C Coinfection : From guesswork to Guidelines. HIV / Hepatitis C CoInfection. HIV infection as a roadmap for HCV and Coinfection HIV/ Hep C Coinfection overview

522 views • 37 slides

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice. Jeff Allen, MD, FAAFP Chief of Health Programs, FBOP Michelle Williams, PharmD Lieutenant, USPHS Hepatitis/HIV Program Manager, FBOP Newton Kendig , MD RADM, Assistant Surgeon General, USPHS

430 views • 34 slides

Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment Success

401 views • 28 slides

HCV in the HIV infected Patient

386 views • 26 slides

?????????

???????????????. ?????????. ?????????. Frequent curability of diverse populations without IFN. IFN-free DAA combinations (GT1). Ribavirin. Suppression of HCV with DAA combination (PI + NI). Potential approval of other DAAs with IFN (eg, faldaprevir). Proof of concept for DAA (PI).

271 views • 26 slides

Future Trials of Hepatitis C Therapy in the HIV Co-infected

Future Trials of Hepatitis C Therapy in the HIV Co-infected. Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases University of Alberta. Ongoing Clinical Trials of HCV Therapy in the HIV Co-infected.

218 views • 9 slides